Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

NCT05850377 is registered in ClinicalTrials.gov with Sociedad de Lucha Contra el Cáncer del Ecuador as lead sponsor.

NCT NCT05850377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05850377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
Lead sponsor
Sociedad de Lucha Contra el Cáncer del Ecuador
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2023
Completion date
May 31, 2026
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, adult, malignant, brain tumor, central nervous system neoplasms, glioma, glioma, malignant, high grade glioma, neoplasm malignant, neoplasms, neuroepithelial, neuroectodermal tumors, photosensitizing agents, tumour, residual